Hepatitis B virus (hepatitis B virus, HBV) infection is a global public health problem, the burden of disease caused in China is very serious, although the implementation of many prevention and control strategies and achieved corresponding results, but China's prevention and control of hepatitis B still faces many challenges, new HBV infections still occur from time to time, chronic HBV infection population management there are also many problems.
Many of these patients feel that although they are HBV infected, they currently have no symptoms, so they neglect to intervene in the treatment of the disease, resulting in a delay in the control of the disease, thus worsening the condition.
In fact, once HBV is detected, antiviral therapy must be carried out according to the doctor's diagnosis to prevent further aggravation of the condition. In particular, the following cases require antiviral therapy as soon as possible.
<h1 class="pgc-h-arrow-right" data-track="28" > what conditions require antiviral treatment as soon as possible? </h1>
People receiving antivirals need to meet the following conditions at the same time;
Treatment is further expanded in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 Edition) to include initiation of antiviral therapy as long as the hepatitis B virus DNA test is positive and alanine transaminasase (ALT) is elevated (excluding other causes). Alanine aminotransferase is normal and should not be taken lightly, and if the patient has high-risk factors, or inflammation of the liver, liver fibrosis, antiviral therapy should be carried out as soon as possible.
For patients with chronic hepatitis B, entecavir and tenofovir disoproxil fumarate are recommended clinically.
On November 8, 2018, China's State Food and Drug Administration approved propofol tenofovir fumarate for the treatment of chronic HBV infection. As an upgraded version of tenofovir disoproxil fumarate, Qilu Pharmaceutical's propofol tenofovir fumarate (Terifolim) will be listed in China in the near future, which is a heavy news for many patients with chronic hepatitis B in China.
<h1 class="pgc-h-arrow-right" data-track="48" >"3 advantages of "propofol fumarate tenofovir" upgraded</h1> version
Propofol tenofovir fumarate has a good effect on reducing serum HBV-DNA levels, inhibiting HBV replication, improving liver function in patients with chronic hepatitis B virus infection, and it also has 3 advantages compared with similar drugs;
(1) ALT (alanine aminotransferase) has a high recurrence rate
Compared with tenofovir disoproxil fumarate, propofol tenofovir fumarate can achieve a higher ALT recurrence rate, further reducing the risk of liver cancer;
(2) Drug resistance is small
Compared with other similar drugs, propofol tenofovir fumarate has a high resistance barrier, and no chronic HBV infection of propofol tenofovir fumarate resistance has been found.
(3) High security
Propofol tenofovir fumarate has high stability and low concentration in the intestine and plasma, and the amount of tenofovir exposed in the blood is also greatly reduced by circulation into the renal tubules, thereby improving the renal safety of propofol tenofovir fumarate and greatly reducing the risk of bone density reduction based on tubular injury.
In summary: Compared with similar drugs, propofol tenofovir fumarate has the characteristics of high recurrence rate, good efficacy and few adverse reactions, which can improve the treatment effect of patients and delay the progression of the disease.
Dosage: One tablet once daily. take orally. Take with food.
Precautions: It should be treated by a physician with experience in the management of chronic hepatitis B.
If one dose is missed during the taking of propofol tenofovir fumarate tablets, but it is less than 18 hours before the last dose, the patient should take a supplement as soon as possible and resume normal dosing time. If the medication has been taken for more than 18 hours, there is no need to make up the medication and it can be continued during the normal dosing time.
If a patient vomits within 1 hour of taking propofol tenofovir fumarate tablets, the patient should take another tablet. If a patient vomits more than 1 hour after taking propofol tenofovir fumarate tablets, the patient does not need to take it again.